Cannabis and Phantom Limb Pain
What the evidence actually says about using cannabis to manage pain in a limb that is no longer there.
Phantom limb pain is one of the hardest chronic pain syndromes to treat, and standard drugs often fail. Cannabis gets a lot of word-of-mouth praise from amputees, but the actual clinical evidence is thin: a handful of case reports, some indirect data from neuropathic pain trials, and almost no PLP-specific randomized trials. It's a reasonable thing to discuss with a doctor if other options have failed — just don't believe anyone who tells you it's a proven treatment. It isn't, yet.
Not medical advice
This article is not medical advice. It is an evidence summary for educational use. Phantom limb pain is complex and often co-occurs with depression, PTSD, and opioid use. Talk to a physician — ideally one familiar with amputee rehabilitation or chronic pain — before starting, stopping, or changing any treatment, including cannabis. Drug interactions, cardiovascular risk, and psychiatric history all matter.
Plain-language summary
Phantom limb pain (PLP) is pain that feels like it's coming from a limb that has been amputated. Estimates suggest 50–80% of amputees experience it at some point [1] Strong evidence. The mechanism is not fully understood but involves peripheral nerve changes (neuromas), spinal cord rewiring, and reorganization in the brain's sensory cortex [1][2] Strong evidence.
Because PLP is partly a neuropathic pain syndrome, people often ask whether cannabis — which has modest evidence for neuropathic pain in general — might help. The honest answer: there is almost no direct evidence for cannabis in PLP specifically. What we have is (a) indirect extrapolation from neuropathic pain trials, (b) a small number of case reports, and (c) survey data showing many amputees self-medicate with cannabis and report benefit Anecdote. That is not the same as a proven treatment.
What probably works (for PLP generally, not cannabis)
To put cannabis in context, here's what mainstream medicine offers for PLP, none of which is a home run:
- Mirror therapy and graded motor imagery — low-risk, modest evidence, often first-line [3] Weak / limited.
- Tricyclic antidepressants (e.g., amitriptyline) — commonly used, evidence in PLP specifically is mixed [4] Weak / limited.
- Gabapentinoids (gabapentin, pregabalin) — widely prescribed; trials in PLP show small or inconsistent effects [4] Weak / limited.
- Opioids — can reduce PLP but carry well-known harms; usually not first-line [4] Weak / limited.
- Targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI) — surgical approaches with growing evidence for reducing residual and phantom pain [5] Weak / limited.
The striking feature of the PLP literature is how often "first-line" treatments fail. That clinical gap is exactly why patients experiment with cannabis.
What might work: cannabis evidence
Direct PLP evidence is sparse. A 2007 Cochrane-style review on pharmacological PLP management did not identify high-quality cannabis trials [4] No data. Subsequent literature has added case reports and small observational series suggesting benefit in individual patients, but not controlled trials specifically in PLP Anecdote.
Indirect evidence comes from neuropathic pain trials. The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report concluded there is substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults, with the strongest signal in neuropathic pain [6] Strong evidence. Effect sizes are modest — roughly a 30% pain reduction in a minority of patients, similar to other adjunctive agents. Whether that generalizes to PLP, which has a strong central/cortical component, is unknown.
Nabiximols (Sativex), a standardized THC:CBD oromucosal spray, has trial data in multiple sclerosis-related neuropathic pain and central pain [7] Strong evidence. Again, no PLP-specific trials of meaningful size.
Survey data from amputees consistently show that those who try cannabis often report it helps pain, sleep, and mood — but these are uncontrolled self-reports with strong selection bias Anecdote.
Bottom line: it is biologically plausible and consistent with the broader neuropathic pain literature that cannabis helps some people with PLP. "Plausible and consistent" is not the same as "proven."
What doesn't work or has weak evidence
- CBD alone for PLP — heavily marketed, but no controlled trials in PLP and weak evidence even in broader neuropathic pain No data.
- Specific strains or "indica vs sativa" recommendations — the indica/sativa distinction does not reliably predict effects and is essentially marketing folklore [8] Disputed. See Indica vs Sativa.
- Terpene-targeted products (e.g., "high myrcene for pain") — the popular "0.5% myrcene threshold" and similar claims are folklore with no clinical trial support No data. See Terpenes.
- Topical cannabis for PLP — topicals don't reach central nervous system targets responsible for PLP. Plausible for residual limb skin pain, not phantom pain No data.
What we don't know
- Whether cannabis modifies the underlying cortical reorganization in PLP, or only dampens pain perception (no data) No data.
- Optimal THC:CBD ratio, dose, or route specifically for PLP No data.
- Whether cannabis interacts usefully — or harmfully — with mirror therapy and graded motor imagery, which depend on intact attention and body schema processing No data.
- Long-term outcomes in amputees using cannabis daily for years, including tolerance and cannabinoid hyperalgesia risk Weak / limited.
- Whether cannabis reduces opioid use in this specific population, as it appears to in some other chronic pain cohorts Weak / limited.
Risks and practical considerations
Cannabis is not benign, especially in a population that often has co-occurring PTSD, depression, sleep disturbance, and polypharmacy.
- Psychiatric: THC can worsen anxiety and, in vulnerable individuals, precipitate psychosis [6] Strong evidence.
- Cognitive: Acute impairment of attention and memory; relevant if you're driving with a prosthesis or operating equipment [6] Strong evidence.
- Cardiovascular: Acute THC use raises heart rate and blood pressure; caution with cardiac history [6] Strong evidence.
- Cannabinoid hyperalgesia / tolerance: Heavy chronic use can paradoxically increase pain sensitivity in some patients Weak / limited.
- Drug interactions: CBD inhibits several CYP450 enzymes; relevant if you take anticonvulsants, warfarin, or certain antidepressants [9] Strong evidence.
- Dependence: Roughly 1 in 10 adult users develop cannabis use disorder; higher with daily use [6] Strong evidence. See Cannabis Use Disorder.
A reasonable approach, if you and your clinician decide to try it: start with a low-THC or balanced THC:CBD product, low dose, ideally a route with predictable pharmacokinetics (oromucosal or oral), track pain and function with a diary, and re-evaluate at 4–8 weeks. If it isn't clearly helping, stop.
Sources
- Peer-reviewed Flor H. (2002). Phantom-limb pain: characteristics, causes, and treatment. The Lancet Neurology, 1(3), 182-189.
- Peer-reviewed Kuffler DP. (2018). Origins of Phantom Limb Pain. Molecular Neurobiology, 55(1), 60-69.
- Peer-reviewed Chan BL, Witt R, Charrow AP, et al. (2007). Mirror therapy for phantom limb pain. New England Journal of Medicine, 357(21), 2206-2207.
- Peer-reviewed Alviar MJM, Hale T, Dungca M. (2016). Pharmacologic interventions for treating phantom limb pain. Cochrane Database of Systematic Reviews, (10), CD006380.
- Peer-reviewed Dumanian GA, Potter BK, Mioton LM, et al. (2019). Targeted Muscle Reinnervation Treats Neuroma and Phantom Pain in Major Limb Amputees: A Randomized Clinical Trial. Annals of Surgery, 270(2), 238-246.
- Government National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
- Peer-reviewed Langford RM, Mares J, Novotna A, et al. (2013). A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology, 260(4), 984-997.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE, 17(5), e0267498.
- Peer-reviewed Brown JD, Winterstein AG. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7), 989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Neuropathic Pain — What the evidence actually says about using cannabis to treat nerve pain, by condition and...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...